

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended) A method of treating uterine serous papillary carcinoma that over-express HER-2/neu, consisting of the step of administering to an individual with said carcinoma a therapeutically effective dose of a humanized murine anti-HER2/neu monoclonal antibody 4D5, wherein said antibody is an IgG1k that contains human framework regions with the complementary-determining regions of the murine monoclonal antibody 4D5 that binds to the extracellular domain of HER-2/neu.

Claims 2-4 (canceled)

Claim 5. (previously presented) The method of claim 1, wherein said antibody is administered to said individual in a dose of from about 4mg/kg to about 8mg/kg.

Claims 6-18. (canceled)